SL44 is an agonist of human caseinolytic protease P (HsClpP) with an EC50 of 1.30 μM. It inhibits LM3 proliferation with an IC50 of 3.1 μM and induces apoptosis in liver cancer cells by degrading respiratory chain complex subunits. In mouse models, SL44 demonstrates antitumor activity without significant toxicity (LD50=400 mg/kg) and exhibits favorable pharmacokinetic properties in rat models.